Hepatitis B virus infection as a risk factor for chronic kidney disease

Fabrizi, Fabrizio; Cerutti, Roberta; Ridruejo, Ezequiel

doi:10.1080/17512433.2019.1657828

Cited by 18 publications

(15 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our population, older age, T2DM, hypertension were associated with the risk of CKD like in the general population [18][19][20][21] . HBV and HCV co-infections were not associated with the risk of CKD in our study although an association with HBV was found in other studies 22,23 and HCV 8 .…”

Section: Discussioncontrasting

confidence: 88%

Chronic Kidney Disease in a Large National Human Immunodeficiency Virus Treatment Program

Paengsai

Noppakun

Jourdain

et al. 2022

Preprint

View full text Add to dashboard Cite

Introduction: Tenofovir disoproxil fumarate (TDF) is associated with a risk of chronic kidney disease (CKD), especially when used with protease inhibitors or in Asian populations. Data from the Thai national health insurance system were used to assess the incidence of CKD in patients receiving antiretroviral therapy (ART) in real-world practice. Materials and methods We analyzed data from patients who initiated one of the following first-line ART regimens: (i) zidovudine+lamivudine+nevirapine (AZT+3TC+NVP); (ii) zidovudine+lamivudine+efavirenz (AZT+3TC+EFV); (iii) tenofovir+lamivudine+nevirapine (TDF+3TC+NVP); (iv) tenofovir+lamivudine/emtricitabine+efavirenz (TDF+3TC/FTC+EFV); and (v) tenofovir+lamivudine+lopinavir/ritonavir (TDF+3TC+LPV/r). CKD was defined as glomerular filtration rate <60 mL/min/1.73 m2 for >3 months, or a confirmed 2010 WHO diagnosis (ICD-10 code N183, N184, or N185). Death competing risks survival regression models were used for the analysis. Results Among 27,313 participants, median age 36.8 years, body mass index 20.4 kg/m2, and absolute CD4 cell count 146 cells/mm3, followed for a median 2.3 years, 245 patients (0.9%) were diagnosed CKD (incidence 3.2 per 1,000 patient-years of follow-up; 95% confidence interval [CI] 2.8-3.6). Compared with patients receiving AZT+3TC+NVP, the risk of CKD measured by adjusted sub-distribution hazard ratio (aSHR) was higher in patients on TDF+3TC+LPV/r (6.5, 95% CI 3.9-11.1), on TDF+3TC+NVP (3.8, 95% CI 2.3-6.0) and on TDF+3TC/FTC+EFV (1.6, 95% CI 1.2-2.3). Among patients receiving TDF, compared with those receiving TDF+3TC/FTC+EFV, the risk was higher on TDF+3TC+LPV/r (4.0, 95%CI 2.3-6.8) on TDF+3TC+NVP (2.3, 95%CI 1.4-3.6) . Conclusions This real-world study suggest that the role of TDF in increasing the risk of CKD, especially when combined with LPV/r or NVP.

show abstract

Section: Discussioncontrasting

confidence: 88%

Chronic Kidney Disease in a Large National Human Immunodeficiency Virus Treatment Program

Paengsai

Noppakun

Jourdain

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…5 Moreover HBV infection itself can lead to glomerular and tubular renal injury and, rarely, to the development of end-stage renal disease. 6 Tenofovir alafenamide (TAF) is a prodrug with a favorable renal safety profile compared with TDF mainly because tenofovir plasma concentrations are reduced by approximately 90%. 7,8 Because the studies that confirmed the renal safety of TAF in HIV/ HBV-infected individuals mainly enrolled individuals without renal impairment, 7,9 we evaluated the impact of replacing TDF with TAF on estimated glomerular filtration rate (eGFR), urine protein-to-creatinine ratio, and alanine aminotransferase (ALT) levels in HIV/HBV-coinfected individuals with renal dysfunction using data from the Swiss HIV Cohort Study (SHCS).…”

Section: Introductionmentioning

confidence: 99%

Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction—A Prospective Cohort Study

Surial

Béguelin

Chave³

et al. 2020

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

Background: Whereas tenofovir disoproxil fumarate (TDF) can lead to renal adverse events, tenofovir alafenamide (TAF) has a more favorable renal safety profile. However, the impact of replacing TDF with TAF on renal function and liver parameters among HIV/hepatitis B virus (HBV)coinfected individuals with renal dysfunction remains unclear. Methods: We included all participants from the Swiss HIV Cohort Study with an HIV/HBV coinfection who switched from TDF to TAF and had an estimated glomerular filtration rate (eGFR) ,90 mL/min/1.73 m 2 and a suppressed HIV viral load (,200 cp/mL). We assessed changes in eGFR, urine protein-to-creatinine ratio, and alanine aminotransferase (ALT) after 1 year using mixed-effect models with interrupted time series. Results: Among 106 participants (15.1% women, median age 53 years), eGFR was 60-89 mL/min/1.73 m 2 in 84 (79.2%) and ,60 mL/min/1.73 m 2 in 22 (20.8%) individuals at the time of switch. One year after the switch from TDF to TAF, individuals with an eGFR between 60 and 89 mL/min/1.73 m 2 experienced increases in eGFR of 3.2 mL/min/1.73 m 2 (95% confidence interval [CI] 1.2 to 5.2), whereas those with an eGFR ,60 mL/ min/1.73 m 2 experienced improvements of 6.2 mL/min/1.73 m 2 (95% CI 2.4 to 10.0). Urine protein-to-creatinine ratio decreased overall (26.3 mg/mmol, 95% CI 210.0 to 22.7), and ALT levels declined in patients with elevated baseline levels (211.8 IU/L, 95% CI 217.3 to 26.4) 1 year after replacing TDF with TAF.

show abstract

“…Whether clinical or laboratory studies, the results showed an association between HBV and CKD. HBV infection may cause kidney damage, however, it is also a risk factor to kidney dysfunction [10,11]. The results from the Chinese Center for Disease Control and Prevention(CDC) of the epidemiology of Hepatitis B survey in those aged 1~29 years in China showed that HBsAg positivity in people aged 1-4 years, 5-14 years and 15-29 years was 0.32%, 0.94% and 4.38%, however, the data decreased by 96.7%, 91.2% and 55.1% when compared to 1992, respectively.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of Entecavir for Hepatitis B virus-associated Glomerulonephritis with renal function insufficient

et al. 2021

Preprint

View full text Add to dashboard Cite

Background HBV-GN is one of the most common secondary kidney diseases in China. Entecavir is one of the first-line antiviral nucleoside drugs at present, which can also effectively apply to antiviral therapy for HBV-GN.Objective The retrospective study to explore whether the entecavir is efficacy and safety for the treatment of Hepatitis B virus-associated glomerulonephritis(HBV-GN) with renal function insufficient.Methods We screened patients diagnosed with HBV-GN in The Affiliated Hospital of Qingdao University, elevated serum creatinine at 130umol/l ~ 250umol/l. Group 1 (30 patients) was given entecavir as antiviral treatment. Group 2 (28 patients) was treated with angiotensin II receptor blocker (ARB). The changes of renal function and the possible influencing factors were observed, with a mean follow-up time of 36 months.Results Baseline demographic and clinical parameters were not different between the 2 groups. For both cohorts, serum creatinine levels were increased gradually and the levels of eGFR declined progressively during the follow-up. At the end of the follow-up, serum creatinine levels in group 1 (t = 1.64, P = 0.1) and in group 2 ( t = 4.35, P = 0.001) were considered statistically significant compared to baseline creatinine. The levels of eGFR in group 1 (t = 2.37, P = 0.0018) and in group 2 ( t = 4.35, P = 0.001) were considered statistically significant compared to baseline eGFR. Comparison between the two groups showed that the elevated serum creatinine level and reduction in the level of eGFR were significantly lower in group 1 (t = 2.67, P = 0.008) than in group 2 (t = 2.76, P = 0.006), which were considered statistically significant. At the same time, cumulative renal survival, using end-stage renal disease (ESRD, eGFR < 15ml/min) as the primary renal endpoint, was 96.7% in group 1 and 67.9% in group 2 respectively (P = 0.005). Meanwhile, urine protein excretion was significantly decreased in both groups compared with baseline values, group 1 (t = 5.74, P = 0.001) and group 2 (t = 4.27, P = 0.001), while no significant difference was found(P = 0.370)in both groups. We performed a multivariate Cox regression analysis required eGFR < 15ml/min as the primary end point, then we found that the entecavir treatment and remission of proteinuria were the protective factors of renal function impairment, while the lower baseline eGFR was the risk factor of the progression of ESRD.Conclusion Entecavir treatment slows the progression of renal function impairment in HBV-GN, meanwhile, entecavir shows a significantly renal protective effect.

show abstract

Hepatitis B virus infection as a risk factor for chronic kidney disease

Cited by 18 publications

References 46 publications

Chronic Kidney Disease in a Large National Human Immunodeficiency Virus Treatment Program

Chronic Kidney Disease in a Large National Human Immunodeficiency Virus Treatment Program

Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction—A Prospective Cohort Study

Efficacy and safety of Entecavir for Hepatitis B virus-associated Glomerulonephritis with renal function insufficient

Contact Info

Product

Resources

About